The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| MBRX | -87.71% | -99.6% | -66.77% | -100% |
| S&P | +12.66% | +85.37% | +13.13% | +226% |
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company. It engages in the business of growing a pipeline including phase 2 clinical programs for hard-to-treat cancers and viruses. The company was founded by Walter V. Klemp, Donald H. Picker, and Waldemar Priebe on July 28, 2015 and is headquartered in Houston, TX.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.02M | 32.3% |
| Market Cap | $26.23M | 207.7% |
| Market Cap / Employee | $1.54M | 0.0% |
| Employees | 17 | -5.6% |
| Net Income | -$25.40M | -139.8% |
| EBITDA | -$5.89M | 17.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $6.70M | -28.7% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.26M | -33.8% |
| Short Term Debt | $0.13M | 13.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -189.07% | -93.2% |
| Return On Invested Capital | -125.42% | -52.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$7.22M | -18.2% |
| Operating Free Cash Flow | -$7.22M | -18.2% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.96 | 327.50 | -1.27 | -0.97 | -185.49% |
| Price to Tangible Book Value | -34.77 | -15.91 | -9.60 | -21.86 | -178.82% |
| Enterprise Value to EBITDA | -0.29 | -0.31 | 0.43 | -2.29 | 884.88% |
| Return on Equity | -141.5% | -135.8% | -214.8% | -503.8% | 480.25% |
| Total Debt | $0.48M | $0.45M | $0.42M | $0.39M | -22.92% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
